login
login

Europe Daily Bulletin No. 8431

28 March 2003
Contents Publication in full By article 42 / 46
ECONOMIC INTERPENETRATION / (eu) biotechnology

Swiss laboratory NOVARTIS is going to acquire 51% of the capital in the US company, IDENIX, which specialises in the development of hepatitis B treatment and anti-virals. NOVARTIS will pay USD 225 million in cash and more than USD one hundred million during the development of the new medicines by the company to obtain its stake.

Contents

A LOOK BEHIND THE NEWS
THE DAY IN POLITICS
GENERAL NEWS
ECONOMIC INTERPENETRATION